Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study

Blood Pressure

Volumn 23, Issue 3, 2014, Pages 181-188

  Redón, Josep ^a   Pascual Izuel, Jose M ^b   Rodilla, Enrique ^b   Vicente, Antonio ^a   Oliván, Josefina ^c   Bonet, Josep ^d   Torguet, Josep Pere ^e   Calaforra, Oscar ^a   Almirall, Jaume ^f  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL DE SAGUNTO   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Hospital Dr Josep Trueta de Girona   (Spain)

^f UDIAT   (Spain)

Author keywords

Atenolol; Augmentation index; Central aortic pressure; Hypertension; Nebivolol; Pulse pressure

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; NEBIVOLOL; ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE;

ACUTE PANCREATITIS; ADD ON THERAPY; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; ARTERIAL PRESSURE; ARTICLE; AUGMENTATION INDEX; BORDERLINE HYPERTENSION; CENTRAL AORTIC PRESSURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTPATIENT; PERIPHERAL ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE; TONOMETER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84901010112     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2013.840421     Document Type: Article

References (23)

1. Dahlöf B, Sever P S, Poulter N R, Wedel H, Beevers D G, Caulfi eld M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofl umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005; 366: 895-906
2. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006; 113: 1213-1225
3. Lindholm LH, Carlberg B, Samuelsson O. S hould beta blockers remain fi rst choice in the treatment of primary hypertension?. A meta-Analysis. Lancet. 2005; 366: 1545-1553. (Pubitemid 41540112
4. Carlberg B, Samuelsson O, Lindholm LH. A tenolol in hypertension: Is it a wise choice?. Lancet. 2004; 364: 1684-1689
5. Khan N, McAlister FA. R e-examining the effi cacy of betablockers for the treatment of hypertension: A meta-Analysis. CMAJ. 2006; 174: 1737-1742
6. Thypertension: Clinical management of primary hypertension in adults. Clinical Guidelines, CG 127. August 2011. http:// www.nice.org.uk/cg127
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105-1187
8. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al.; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J. 2006; 27: 2588-2605
9. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. atenolol and eprosartan: DifferentiaLeffects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006; 19: 214-219. (Pubitemid 43350177
10. Pannier BM, Guerin A P, Marchais SJ, London GM. D ifferent aortic refLection wave responses following long-Term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol. 2001; 28: 1074-1077. (Pubitemid 34053527
11. Chen C H, Ting C T, Lin S J, Hsu TL, Yin F C, Siu C O, et al. Different effects of fosinopril and atenolol on wave refLections in hypertensive patients. Hypertension. 1995; 25: 1034-1041
12. Pedersen M E, Cockcroft J R. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007; 9: 269-277
13. McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004; 44: 305-310. (Pubitemid 39167227
14. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008; 26: 351-356
15. Mahmud A, Feely J. B eta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave refLection. Am J Hypertens. 2008; 21: 663-667. (Pubitemid 351733365
16. SAS I nstitute Inc. S AS/STAT User s Guide, 6th version. 4th ed. Cary, NC: SAS Institute Inc .; 1989
17. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. DifferentiaLeffects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011; 57: 1122-1128
18. Mahmud A, Feely J. B eta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave refLection. Am J Hypertens. 2008; 21: 663-667. (Pubitemid 351733365
19. Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, et al. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens. 2011; 5: 161-165
20. Pol ón ia J, Barbosa L, Silva J A, Bertoquini S. D ifferent patterns of peripheral versus central blood pressure in hypertensive patients treated with ® -blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010; 15: 235-239
21. Vitale C, Marazzi G, Iellamo F, Spoletini I, Dallarmi V, Fini M, et al. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newlydiagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol. 2012; 155: 279-284
22. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi A, Falqui V, et al. Increased ambulatory arterial stiffness index is associated with target organ Damage in primary hypertension. Hypertension. 2006; 48: 397-403. (Pubitemid 44253732
23. Garc í a-Ortiz L, Recio-Rodrí guez J I, Mart ín -Cantera C, Cabrejas-S á nchez A, Gó mez-Arranz A, Gonz á lez-Viejo N, et al.; EVIDENT Group. PhysicaLexercise, fi tness and dietary pattern and their relationship with circadian blood pressure pattern, AIx and endothelial dysfunction biological markers: EVIDENT study protocol. BMC Public Health. 2010; 10: 233